KR102453573B1 - 항-pacap 항체 - Google Patents
항-pacap 항체 Download PDFInfo
- Publication number
- KR102453573B1 KR102453573B1 KR1020207008789A KR20207008789A KR102453573B1 KR 102453573 B1 KR102453573 B1 KR 102453573B1 KR 1020207008789 A KR1020207008789 A KR 1020207008789A KR 20207008789 A KR20207008789 A KR 20207008789A KR 102453573 B1 KR102453573 B1 KR 102453573B1
- Authority
- KR
- South Korea
- Prior art keywords
- residue
- antibody
- alanine
- threonine
- tryptophan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565278P | 2017-09-29 | 2017-09-29 | |
| US62/565,278 | 2017-09-29 | ||
| PCT/US2018/051898 WO2019067293A1 (en) | 2017-09-29 | 2018-09-20 | ANTI-PACAP ANTIBODIES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200040881A KR20200040881A (ko) | 2020-04-20 |
| KR102453573B1 true KR102453573B1 (ko) | 2022-10-12 |
Family
ID=63794713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207008789A Active KR102453573B1 (ko) | 2017-09-29 | 2018-09-20 | 항-pacap 항체 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10519225B2 (https=) |
| EP (1) | EP3688035A1 (https=) |
| JP (2) | JP6952888B2 (https=) |
| KR (1) | KR102453573B1 (https=) |
| CN (1) | CN111164105B (https=) |
| AR (1) | AR113022A1 (https=) |
| AU (1) | AU2018341959B2 (https=) |
| BR (1) | BR112020003628A2 (https=) |
| CA (1) | CA3077304C (https=) |
| CL (1) | CL2020000705A1 (https=) |
| CO (1) | CO2020002170A2 (https=) |
| CR (1) | CR20200127A (https=) |
| DO (1) | DOP2020000060A (https=) |
| EA (1) | EA202090563A1 (https=) |
| EC (1) | ECSP20020293A (https=) |
| IL (1) | IL273529A (https=) |
| JO (1) | JOP20200069A1 (https=) |
| MA (1) | MA50654A (https=) |
| MX (1) | MX2020003563A (https=) |
| MY (1) | MY199876A (https=) |
| NZ (1) | NZ762312A (https=) |
| PE (1) | PE20201494A1 (https=) |
| PH (1) | PH12020550340A1 (https=) |
| SG (1) | SG11202002572YA (https=) |
| TW (1) | TWI701260B (https=) |
| WO (1) | WO2019067293A1 (https=) |
| ZA (1) | ZA202001058B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2982861A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| EP3426288A4 (en) | 2016-04-15 | 2019-10-30 | Alder Biopharmaceuticals, Inc. | ANTI-PACAP ANTIBODIES AND USES THEREOF |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| WO2023010065A2 (en) * | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| CN117916259A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cgrp和pacap的抗原结合分子及其医药用途 |
| KR102839881B1 (ko) * | 2021-11-19 | 2025-07-31 | 대한민국 | 방송통신기자재 성능 측정 시스템 및 그 방법 |
| WO2024218541A1 (en) * | 2023-04-20 | 2024-10-24 | Mark Hasleton | Treatment of migraine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014786A1 (en) | 1990-03-17 | 1991-10-03 | Takeda Chemical Industries, Ltd. | Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap |
| US20160304604A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| WO2017106578A1 (en) * | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037321A (en) | 1995-05-03 | 2000-03-14 | Biostar Inc. | Fusion proteins comprising vasoactive intestinal peptide or PACAP |
| FR2826747B1 (fr) | 2001-07-02 | 2005-02-25 | Gemplus Card Int | Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce |
| US7615219B2 (en) | 2003-01-16 | 2009-11-10 | Life Sciences Research Partners Vzw | Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
| WO2012106407A2 (en) | 2011-02-01 | 2012-08-09 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
| JP6064861B2 (ja) | 2013-03-05 | 2017-01-25 | 株式会社デンソー | 熱電変換装置の製造方法 |
| CA2906737C (en) * | 2013-03-15 | 2023-08-15 | Amgen Inc. | Human pac1 antibodies |
| EP3035950A4 (en) | 2013-08-14 | 2017-05-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases |
| WO2017142961A1 (en) | 2016-02-16 | 2017-08-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Treatment of traumatic brain injury or stroke |
-
2018
- 2018-09-13 AR ARP180102618A patent/AR113022A1/es not_active Application Discontinuation
- 2018-09-14 TW TW107132467A patent/TWI701260B/zh active
- 2018-09-20 MA MA050654A patent/MA50654A/fr unknown
- 2018-09-20 KR KR1020207008789A patent/KR102453573B1/ko active Active
- 2018-09-20 CA CA3077304A patent/CA3077304C/en active Active
- 2018-09-20 CN CN201880063106.2A patent/CN111164105B/zh active Active
- 2018-09-20 SG SG11202002572YA patent/SG11202002572YA/en unknown
- 2018-09-20 WO PCT/US2018/051898 patent/WO2019067293A1/en not_active Ceased
- 2018-09-20 EA EA202090563A patent/EA202090563A1/ru unknown
- 2018-09-20 BR BR112020003628-5A patent/BR112020003628A2/pt not_active Application Discontinuation
- 2018-09-20 NZ NZ762312A patent/NZ762312A/en not_active IP Right Cessation
- 2018-09-20 MY MYPI2020001596A patent/MY199876A/en unknown
- 2018-09-20 JO JOP/2020/0069A patent/JOP20200069A1/ar unknown
- 2018-09-20 CR CR20200127A patent/CR20200127A/es unknown
- 2018-09-20 US US16/136,490 patent/US10519225B2/en active Active
- 2018-09-20 EP EP18783282.9A patent/EP3688035A1/en active Pending
- 2018-09-20 JP JP2020517489A patent/JP6952888B2/ja active Active
- 2018-09-20 PE PE2020000375A patent/PE20201494A1/es unknown
- 2018-09-20 AU AU2018341959A patent/AU2018341959B2/en not_active Ceased
- 2018-09-20 PH PH1/2020/550340A patent/PH12020550340A1/en unknown
- 2018-09-20 MX MX2020003563A patent/MX2020003563A/es unknown
-
2019
- 2019-11-22 US US16/692,236 patent/US10954292B2/en active Active
-
2020
- 2020-02-19 ZA ZA2020/01058A patent/ZA202001058B/en unknown
- 2020-02-27 CO CONC2020/0002170A patent/CO2020002170A2/es unknown
- 2020-03-16 DO DO2020000060A patent/DOP2020000060A/es unknown
- 2020-03-18 CL CL2020000705A patent/CL2020000705A1/es unknown
- 2020-03-23 IL IL273529A patent/IL273529A/en unknown
- 2020-03-26 EC ECSENADI202020293A patent/ECSP20020293A/es unknown
-
2021
- 2021-02-15 US US17/175,870 patent/US20210171616A1/en not_active Abandoned
- 2021-09-28 JP JP2021157701A patent/JP7221352B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014786A1 (en) | 1990-03-17 | 1991-10-03 | Takeda Chemical Industries, Ltd. | Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap |
| US20160304604A1 (en) | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Anti-pacap antibodies and uses thereof |
| WO2017106578A1 (en) * | 2015-12-15 | 2017-06-22 | Amgen Inc. | Pacap antibodies and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102453573B1 (ko) | 항-pacap 항체 | |
| CN113896790B (zh) | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途 | |
| CN106715471B (zh) | 抗cd127的抗体 | |
| CN101827609B (zh) | 抗人神经生长因子的高亲和力人抗体 | |
| NZ793343A (en) | Anti- LAG-3 antibodies and compositions | |
| KR20140059168A (ko) | 시신경 척수염 치료용 조성물 및 치료 방법 | |
| KR20090088950A (ko) | 가공된 항-ｔｓｌｐ 항체 | |
| BG107483A (bg) | Антитела с двойна специфичност и методи за тяхното получаване и за тяхното използване | |
| IL167436A (en) | Human anti- ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors | |
| EA023406B1 (ru) | Антитела к гепцидину и варианты их применения | |
| JP7727633B2 (ja) | イヌインターロイキン－４受容体αに対する抗体 | |
| KR20210025071A (ko) | Cd226 효능제 항체 | |
| KR101634636B1 (ko) | 개량형 인간화 항-인간 α9 인테그린 항체 | |
| CN108601833B (zh) | 甲状旁腺激素-抗rankl抗体融合化合物 | |
| CN112175087B (zh) | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 | |
| JP2020524988A (ja) | 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用 | |
| AU2021202092A1 (en) | Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders | |
| CN114053403A (zh) | 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途 | |
| CN114945593B (zh) | 抗IL-1β抗体 | |
| CN114874330B (zh) | 靶向单链抗体的中和性单克隆抗体 | |
| CN121108346B (zh) | 抗ly6g6d单域抗体及其制备方法和用途 | |
| TWI918704B (zh) | Ｃｃｒ８抗體及其應用 | |
| US11873340B2 (en) | Anti-CD11D antibodies and uses thereof | |
| EA040300B1 (ru) | Анти-pacap антитело | |
| HK1250046B (zh) | 抗dkk-1-抗rankl双特异性抗体化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20200326 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200326 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220228 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220927 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221006 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20221007 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |